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A b s t r a c t  
Acyclovir (ACV) is an antiviral drug, used for treatment of herpes simplex virus infections with an 
oral bioavailability of only 10 to 20 % (limiting absorption in GIT to duodenum and jejunum),half-life 
about 3 hrs, soluble at acidic pH (pKa 2.27) and distilled water at 37ºC. Polymeric nano drug 
delivery systems of ACV have been designed and optimized. Poly (lactic-co-glycolic acid) (PLGA) 
(50:50) was used as polymer and Pluronic F68 was stabilizer. In vitro evaluation of prepared 
formulations showed drug entrapment up to 90.06 % and particle size from 395nm. Drug: Polymer 
ratio and concentration of stabilizer were found to influence the particle size and entrapment 
efficiency of ACV loaded PLGA nanoparticles (NPs). In vitro drug release studies indicated 
controlled and sustained drug release of drug for a period of 32 hours. In vivo evaluation was carried 
out for selected formulations in comparison with marketed tablet (Zovirax®) in rabbits. The AUC 
values for developed formulations clearly indicated two to three fold improvement in bioavailability of 
ACV when compared to Zovirax® tablets. These preliminary results indicate ACV NPs are superior 
to marketed tablet Zovirax® as particle size and release rate of entrapped drug is controlled, which 
results in enhanced bioavailability and probable decrease in dose and dosing frequency. Ultimately 
increasing adherence to drug therapy and patient comfort. 
Keywords: Acyclovir, PLGA, nanoparticles, 3ñ factorial design, sustained release, in vitro-in vivo 
evaluation.. 
 
Introduction 
Herpes simplex virus (HSV) has affected more than one third of the 
worldÊs population, also it is believed that the prevalence of HSV in 
the general population in Asian countries is about 30% to 70% and 
is responsible for a wide array of human diseases, with effects 
ranging from discomfort to death.[1] In India, it is believed that 60% 
of sexually active adults carry Herpes viruses. Currently world-
wide, approximately 86 million people are infected with genital 
herpes. Genital herpes is the very common infection in Human 
Immuno deficiency Virus (HIV) positive persons.[2] In fact, from 
60% to 85% of persons with HIV have HSV-2 antibodies. People 
who have genital herpes are more likely to acquire HIV than those 
who don't have the virus. Both Genital herpes (GH) and HIV can be 
sexually transmitted.[3] 
Currently, the only treatments available for genital herpes are 
conventional tablets and topical gel for application on outbreaks. 
The drugs that are commonly used for genital herpes are ACV, 
Valaclovir and Famciclovir. In spite of the addition of new 
antiherpes drugs (Famciclovir and Valacyclovir), ACV has been 
regarded as the original gold standard of therapy, a widely 
prescribed and reliable drug. Conventional dosage forms for the 
treatment of genital herpes infection has a dosage regimen which 
is difficult and very rigorous. The adult dose of ACV, whose oral bio 
availability is only 10 to 30% and the half life is about 3 hrs, is 200 
mg five times daily, for the treatment of primary genital herpes 
infections.[4] Treatment and control of Genital Herpes infections 
can also be extremely beneficial in reducing the incidence of HIV 
infections as well. In view of the difficulties like high dose, frequent 
dosing regimen and side effects, associated with adhering to 
therapy with the presently available conventional dosage forms, a 
new treatment modality for genital herpes infections is the need of 
the day. 
NPs are solid colloidal polymeric carrier systems having particle 
size between 1 to 1000 nm. The polymeric NP have been 
developed as a promising tool for controlled drug delivery systems 
wherein the active drug is encapsulated, entrapped, adsorbed or 
conjugated with the polymer. The application of biodegradable 
polymeric NP in controlling drug delivery has generated immense 
interest in recent times. Biodegradable NP can be successfully 
used for modulating the drug release profile by controlling the 
polymer degradation. One of the best known biodegradable 
carriers for controlled and sustained release is poly (lactide-co-
glycolide) (PLGA). Features such as biocompatibility, prediction of 
biodegradation kinetics, ease of fabrication and regulatory approval 
has attracted its attention for a variety of biomedical applications.[5] 
Moreover, both hydrophilic and lipophilic drugs can be successfully 
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encapsulated in the PLGA matrix. PLGA has been used for 
delivery of drugs for both oral and parenteral routes.[5] PLGA 
degrades in vivo to lactic and glycolic acids, which are 
subsequently eliminated as carbon dioxide and water via the Krebs 
cycle.5 The release of drug from the NPs depends on polymer 
degradation, which is governed by the nature of copolymer 
composition and its molecular weight. For this study, we used 
PLGA 50:50, which is known to hydrolyze at a faster rate than 
those containing a higher proportion of polylactic acid.  
Materials and Methods 
Materials 
ACV was a gift sample from M/S Ajanta Pharmaceuticals Ltd, 
Research and Development Division, Mumbai. poly DL-lactide-co- 
glycolide (50/50 DL-PLGA) inherent viscosity: 0.58 dL/g 
MW75,000ă80,000 Da was purchased from Sigma Aldrich, India. 
Poloxamer 188 (F-68) was obtained as gift samples from M/S 
Glenmark Pharmaceutical Ltd. Nashik, India. Acetone, cellophane 
membrane etc. were  purchased from S.D. Fine Chem. Ltd., 
Mumbai, India. All other reagents and chemicals used in this study 
were of analytical grade. 
Formulation of poly (lactic-co-glycolic acid) (PLGA) NPs 
PLGA NPs were prepared by the solvent deposition method.6 ACV 
was dissolved in neutral water (pH =7) kept at 35-40ĈC containing a 
hydrophilic stabilizer (Pluronic F68) at various concentrations. 
PLGA (50:50) was solubilized in acetone (40ml) at various 
concentrations. The organic phase was poured into the aqueous 
solution drop wise, under stirring (RPM 5000) for 2 h, thus forming 
a milky colloidal suspension. The organic solvent was then 
evaporated by using a rota evaporator. The resultant dispersion 
was dried using a freeze drying method. 
Experimental Design 
The formulations were fabricated according to a 3ñ full factorial 
design, allowing the simultaneous evaluation of two formulation 
variables and their interaction.  The experimental designs with 
corresponding formulations are outlined in table 1.  The dependent 
variables that were selected for study were particle size (Y1), and 
% drug entrapment (Y2). 
 
Table 1. Experimental design and particle properties of 3ñ Full Factorial Design Formulations  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**All values are represented as mean standard deviation 
* For PLGA (50:50) (X1) transformed levels in drug: polymer ratios are: ă1= 1:1; Â0Ê=1:1.5, +1=1:2, 
# For surfactant (Pluronic F68) (X2) transformed levels in % are: ă1=0.25; Â0Ê=0.5, +1= 1            
 
In Vitro evaluation of the prepared NPs 
% Free drug and % entrapped drug 
i Estimation of Free Drug 
The free drug (per 50mg of formulation) was estimated by taking 
said quantity of formulation in dialysis bag (cellophane membrane, 
molecular weight cut off 12000-14000 Da, Hi-Media, India) which 
was tied  and placed into 100ml 0.1N HCL on magnetic stirrer. At 
pre-determined time intervals, 5ml of the sample was withdrawn by 
means of a syringe. The volume withdrawn at each interval was 
replaced with the same quantity of fresh media. The samples were 
analyzed for free drug by measuring the absorbance at 252nm 
using UV-visible spectrophotometer (Shimadzu UV-1700) after 
suitable dilutions. Above described process of withdrawing sample 
and analysis was continued for each half minute till a constant 
absorbance was obtained for consecutive three readings.[7] 
Estimation of encapsulated drug 
Formulation 
Code X1
* X2# 
% drug 
entrapmentμS
D** 
Particle size 
(nm) 
μSD** 
Poly 
dispersity 
indexμSD** 
F1 +1 +1 64.06μ5.3 1230.3μ67.4 0.65μ0.01 
F2 +1 0 81.32μ7.3 1310.4μ87.1 0.50μ0.03 
F3 +1 -1 90.06μ8.9 1500.2μ97.2 0.77μ0.01 
F4 0 +1 66.24μ5.9 1030.5μ88.7 0.66μ0.05 
F5 0 0 82.36μ7.6 1074.6μ85.1 0.32μ0.02 
F6 0 -1 94.5μ8.4 1130.7μ63.8 0.31μ0.05 
F7 -1 +1 54.36μ5.3 395.9μ33.1 0.74μ0.07 
F8 -1 0 74.36μ6.8 580.7μ41.9 0.44μ0.04 
F9 -1 -1 84.67μ6.4 925.2μ76.3 0.59μ0.05 
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Encapsulated drug (per 50mg of formulation) was estimated by 
taking the residue formulation remained in dialysis membrane after 
estimation of free drug content, as described above. Quantity 
remains in dialysis membrane was added to acetone (10ml) to 
dissolve PLGA and filtered. Residue remaining on filter paper was 
dissolved in 0.1N HCL and after removing supernatant, sample 
was analyzed for drug content by measuring the absorbance at 
252nm using UV-visible spectrophotometer (Shimadzu UV-1700) 
after suitable dilution. The percentage of drug entrapped and the 
percentage of free drug are calculated by following Eq. 
Formulae to calculate % free drug and % drug entrapment, 
 
                         Amount of free drug present in 50mg of formulation 
1) % free drug =   -------------------------------------------------          ï 100 
                     Total amount of drug present in 50mg of formulation  
 
Amount of encapsulated drug present in 50mg of formulation 
2) % Drug entrapment =   --------------------------------------------ï 100 
                       Total amount of drug present in 50mg of formulation 
 
Particle Size and polydispersity analysis 
The particle size and size distribution of the ACV loaded PLGA 
NPs were characterized by laser light scattering method using 
Particle Size Analyzer (Zetasizer 1690S, Malvern UK). 
Development of polynomial equations 
The results from factorial design were evaluated using PCP Disso 
2000 V3 software.  Step-wise backward linear regression analysis 
was used to develop polynomial equations for dependent variables  
particle size (Y1)  and % drug entrapment (Y2) which bear the form 
of equation-1: 
Y=b0+b1X1+b2X2+b12X1X2+b11
2
1X +b22
2
2X  ..............⁄1 
 
Where Y is dependent variable, b0 arithmetic mean response of 
nine batches, and b1 estimated coefficient for factor X1.  The main 
effects (X1 and X2) represent average result of changing one factor 
at a time from its low to high value.  The interaction term (X1X2) 
shows how the response changes when two factors are 
simultaneously changed. The polynomial terms ( 21X  and
2
2X ) are 
included to investigate non-linearity. 
% Yield  and Flow properties of NPs 
Dried NPs were accurately weighed, and by considering the total 
amount of drug and polymers used for preparing the feed solution, 
the yield of production (YP) was calculated, as a percentage, using 
the following equation[8], 
                                                         
          NPs 
     YP =                                                           ï  100 
                        PLGA+ACV+SURFACTANT 
 
Where NPs stands for the amount of produced NPs and 
(PLGA+ACV+ SURFACTANT) for the sum of the amounts of 
Polymer (PLGA), ACV and surfactant for the preparation of NPs. 
Flow properties were assessed by measuring the angle of repose 
by fixed funnel method and compressibility index (CarrÊs index). 
The bulk density and tapped density were measured and the 
compressibility index was calculated using the formula[8], 
Compressibility index or CarrÊs index (I) 
 
      Tapped density - Bulk density 
  I   =                                                                           ï 100 
                               Tapped density  
Surface Morphology / (Scanning Electron Microscopy) 
The microscopic appearance of the coated and uncoated NPs, was 
observed under optical and scanning electron microscopes (Jeol 
JSM-5410 LV, Tokyo, Japan). The scanning electron microscope 
photomicrographs were taken at 15 kV in various magnifications 
appropriate to each formulation. 
Thermal studies (DSC) 
DSC is very useful tool in the investigation of thermal properties of 
prepared dosage form (NPs) and can provide both qualitative and 
quantitative information about the physicochemical state of the 
drug inside the NPs. The absence of endothermic peak indicated 
the amorphous nature of drug in the NPs. Differential scanning 
calorimetry (DSC) was conducted using Mettler Toledo Star 
System, Diya labs, Mumbai, India. Samples were weighed (1.00-
4.00 mg) and placed in sealed aluminium pans. The coolant was 
liquid nitrogen. The samples were scanned at 10oC/ min from 10oC 
to 300oC were carried out. The thermograms are shown in Figure 
4. 
X-Ray Diffraction studies (XRD) 
X-ray diffraction patterns of the ACV loaded NPs were determined 
using a diffractometer equipped with a rotating target X-ray tube 
and a wide-angle goniometer in Diya Labs., Mumbai, India. The X-
ray source was Ká radiation from a copper target with graphite 
monochromater. The X-ray tube was operated at a potential of 50 
kV and a current of 150 mA. The range (2è) of scans was from 0 to 
70o and the scan speed was 2o per minute at increments of 0.02o. 
The obtained results are shown in Figure 5. 
In vitro drug release studies and release kinetics 
NPs retained in dialysis bag after separation from free drug as 
described earlier, were taken for further drug release study. 
Separated NPs were transferred to a flask containing 50 ml 
phosphate buffer saline (pH 7.4).  The entire system was then kept 
at 37μ0.5ĈC with continuous magnetic stirring at 100 rpm. Required 
quantity (5ml) of the medium was withdrawn at specific time 
periods (1, 2, 3, 4, 6 , 8,10, 12, 24, 32, 48 hours) and same volume 
of dissolution medium was replaced in the flask to maintain a 
constant medium volume.[9] The withdrawn samples were filtered 
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and then 5 ml of the filtrate was made up to volume with 100 ml 
media. The samples were analyzed for drug release by measuring 
the absorbance at 252nm using UV-visible spectrophotometer 
(Shimadzu UV-1700). 
To study the underlying mechanism of drug release, drug release 
data was computed by the use of following mathematical models; 
zero-order kinetics, first-order kinetics and Higuchi kinetics;  
Qt = k0t 
 
ln(Q0-Qt)= lnQ0-k1t 
 
Qt = Kh.tó 
 
The following plots were made; Qt vs t (Zero-order kinetic model), 
ln(Q0-Qt) vs t (First-order kinetic model) and Qt vs tó (Higuchi 
model). Where Q0 is the initial amount of drug present in the 
microspheres, Qt is the amount of drug released at time t and k0, 
k1, and kh are the constants of the above-mentioned equations. In 
order to define a model, which would represent a better fit for the 
formulation, dissolution data was further analyzed by Korsmeyer-
peppas equation, 
Mt / M¥ = ktn 
Where Mt is the amount of drug released at time t and M¥ is the 
amount of drug released at time ¥, thus the Mt/M¥ is the fraction of 
drug released at time t. k is the kinetic constant and n is the 
diffusion exponent, a measure of the primary mechanism of drug 
release. r2 values were calculated for the linear curves obtained by 
regression analysis of the above plots. 
HPLC analysis 
Standardization of HPLC method for the quantification 
of ACV in rabbit plasma 
To quantify ACV in plasma, HPLC method was standardized. 
Precipitation technique was followed for the extraction of ACV from 
plasma. 
Instrumentation 
The method was developed using HPLC isocratic system with a 
UVăDetector. Chromatographic analysis was carried out at 
ambient temperature. The mobile phase for plasma samples 
consisted 0.03M phosphate buffer / methanol / acetonitrile 
(35:40:25) adjusted to pH 4 with phosphoric acid and C18 column 
as the stationary phase. The flow rate was maintained at 1.5 
mL/min and detection wavelength was 252nm. The volume of 
injection was 50øL. 
Sample Preparation and Analysis 
 Frozen rabbit plasma was thawed at room temperature, vortexed 
for 10 sec, and any residual clots removed. An aliquot (100 μL) of 
serum was mixed with 100 μL of acetonitrile and the mixture was 
vortexed (Thermolyne Corporation, Maxi 11, Dubuque IA) for 30 
seconds and centrifuged at 8000 rpm for 10 minutes. A 50μL 
sample of the clear supernatant was injected onto the HPLC 
system. Peak areas were used for the determination of drug 
concentrations in the analyzed samples. 
In vivo evaluation of NPs 
In vivo Study Design 
The albino rabbit has been shown to be a good animal model for in 
vivo drug release studies when using ACV as the model drug. In 
this study, six albino rabbits weighing 1.5 and 2.4 kg (average 
weight of 1.858μ0.12 kg) were selected. The study was conducted 
in accordance with standard institutional ethical committee 
guidelines. The rabbits were fasted overnight for 12 hours with free 
access to water. In order to eliminate inter-subject variability 
among animals, the study design was a balanced Latin-Square 
cross-over design with three experimental formulations.  
Experimental Design 
Each animal received one formulation or dose at each study period 
as a single oral dose of 10 mg/kg in a Latin-Square- cross-over 
design with a one week washout period to reuse the animals. The 
test formulation was given to each rabbit orally in suspension form 
with oral snode at a dose of 10 mg of ACV per kg of body weight. 
Collection of blood samples 
The blood samples (approximately 300-400 øL) were collected 
from the marginal ear vein at 0, 0.5, 1, 2, 3, 4, 6, 12, and 24 hours 
after oral administration of test formulations. A washout period of 7 
days was allowed between the first and second trials in individual 
subjects. 
Collection of Blood Plasma 
The blood samples were collected into a heparinized Eppendorf 
tube. Then the samples were subjected to centrifugation on a 
laboratory centrifuge (Sigma, 3K30) at 10000 rpm for 15 minutes at 
0ĈC, and supernatant plasma was collected into another Eppendorf 
tube and kept at ă20ĈC or freeze it until analysis. 
Pharmacokinetic Analysis 
Data were generated assuming first-order absorption and non-
compartment model with first-order elimination. The maximum 
plasma concentration (C
max
) and time of its occurrence (T
max
) were 
directly computed from the plasma concentration vs. time plot. The 
elimination rate constant (K
el
) was determined from the terminal 
phase of plasma concentration vs. time profile by least squares 
regression analysis. From this, K
el 
was calculated as K
el 
= 2.303 x 
slope. The elimination half-life (t
1/2
) was calculated using the 
formula t1/2 = 0.693 / Kel. The absorption rate constant (Ka) was 
calculated using the Wagner-Nelson method equation. All other 
pharmacokinetic parameters like volume of distribution (Vd), Total 
body clearance (CL/F), mean residence time (MRT), area under 
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the first-moment curve (AUMC), were calculated using WinNonlin 
software (Standard Version 1.5). 
Statistical analysis 
All statistical analysis was undertaken using ANOVA test followed 
by using Tukey-Kramer Multiple Comparisons Test (Graph Pad 
Instat3 software) for multiple comparisons at pª0.0001. 
Result and Discussion 
Preparation of NPs 
PLGA NPs were prepared by the solvent deposition method using 
acetone as organic phase and water containing drug and stabilizer 
as aqueous phase. The formulations were fabricated according to 
a 3ñ full factorial design, drug: polymer ratio and concentration of 
stabilizer were selected as independent variable whereas particle 
size and % drug entrapment as dependent variables.  
% Free drug and % entrapped drug 
From Table 1. it is revealed that as drug:polymer (ACV:PLGA) ratio 
increased from 1:1 to 1:2 drug entrapment increases but thereafter, 
further increase in drug : polymer ratio showed reduced or 
insignificant change in the drug entrapment efficiency (p º 0.05). 
This can be explained by observing drug entrapment efficiency of 
factorial formulations F3, F6, F9 where Drug:Polymer ratio 
increased from 1:1,1:1.5 and 1:2 respectively with constant 
concentration of stabilizer ( Pluronic F68) i.e. 0.25%. Drug 
entrapment efficiency increased from 84.67% to 94.5% and then 
decreases it to 90.06 %. It also observed that as percentage of 
stabilizer increased from 0.25% to 1% entrapment efficiency 
decrease significantly (pª0.001), the same can be explained with 
respective to factorial formulation F1, F2, F3 where Drug: Polymer 
ratio is constant i.e.1:2 and concentration of stabilizer decreased 
from 1% to 0.25%, drug entrapment efficiency increased from 
64.06% to 90.06%. Thus it can be stated that the amount of 
stabilizer and polymer has an effect on the % drug entrapment of 
NPs. If the concentration of stabilizer is too low, aggregation of the 
polymer will take place, whereas, if too much stabilizer is used, 
drug incorporation could be reduced as a result of the interaction 
between the drug and stabilizer. 
Particle size and polydispersity  analysis 
The mean diameters of the ACV loaded PLGA NPs are presented 
in Table 1. All NPs prepared showed discrete spherical 
appearance with mean diameters in the range of 395.9 nm to 1500 
nm. The polydispersity index (PI) varied from 0.31ă0.77, indicating 
higher particle size distribution. 
From Table 1. it is revealed that as drug : polymer (ACV : PLGA) 
ratio increased from 1:1 to 1:2  particle size increased significantly 
(pª0.001). It also observed that as percentage of stabilizer 
increased from 0.25% to 1% particle size decrease significantly 
(pª0.001). For factorial formulation F1, F2, F3 where Drug: Polymer 
ratio is constant i.e.1:2 and concentration of stabilizer decreased 
from 1% to 0.25%, particle size increased from 1230nm to 
1500nm. From the observed particle size of factorial formulations it 
can be conclude that the effect of the concentration of the polymers 
tested is negative or positive. A positive effect would imply that 
increasing the concentration causes the emulsion to have larger 
droplets, hence leading to larger particles. A negative effect means 
that increasing the concentration causes the emulsion to be more 
stable, hence leading to smaller particles.[10]   
Development of polynomial equations for dependent 
variables 
From the data of Experimental design and Parameters (Table 1.) 
for factorial formulations F1 to F9, polynomial equations for two 
dependent variables (particle size and % drug entrapment) have 
been derived using PCP Disso 2000V3 software. 
The equation derived for particle size is: 
Y1= 1.0193 + 0.3567 X1 - 0.1500 X2                                     
⁄2 
The equation derived for % drug entrapment is: 
Y2=83.49 + 3.6750 X1 - 14.095X2   - 6.2283 X12 ă 3.6983 X22                           
⁄3 
In equations (2) negative sign for coefficient of X2 indicates that the 
particle size of NPs increases when concentration of stabilizer 
(Pluronic F 68) is decreased and positive sign for coefficient of X1 
indicate positive effect of polymer concentration (PLGA ) on 
particle size . 
In equation (3) positive sign for coefficient of X 1 indicates that the 
% drug entrapment increases when concentration of polymer 
(PLGA) increases and negative sign for coefficient of X2 indicates 
that % drug entrapment of NPs increases when concentration of 
stabilizer (Pluronic F 68) decreases. 
Graphical presentation of the data can help to show the 
relationship between response and independent variables. Graphs 
gave information similar to that of the mathematical equations 
obtained from statistical analysis. The response surface graphs for 
particle size and % drug entrapment are presented in Figure 1 and 
2 respectively. 
Based on highest % drug entrapment and lowest particle size 
(below 1100 nm) batches F5, F8, and F9 were chosen to carry out 
the further evaluation study. 
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Figure 1.Response surface plot showing effect of factorial variables (Drug : Polymer ratio and  concentration of stabilizer) on particle size (Y1) in 
nm 
 
% Yield and Flow properties 
The percentage practical yield varies between 70.51%  to  81.78%. 
All the formulations were found to be free flowing i.e. non sticky 
and white powdery in appreance. 
The flow properties of all the formulations were found out by 
measuring the angle of repose by fixed funnel method and 
compressibility index (CarrÊs index). The results are shown in Table 
2. The values of angle of repose were of the range 24Ĉ to 29Ĉ, 
which are within the normal acceptable range of 20Ĉă40Ĉ. Drug 
loaded PLGA NPs thus showed reasonably good flow potential. 
This is further substantiated by the values of Compressibility index 
(I) which was in the range 11.43-13.77, indicating good flow 
characteristics of the powder. This also implies that prepared 
PLGA NPs are nonaggregated.  
 
 
Table 2. % Yield and Flowability properties of PLGA NPs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation Code % Yield CarrÊs IndexμSD** Angle of repose (À)μSD** 
F1 81.78μ3.24 12.77μ1.5 25μ1.3 
F2 80.33μ2.92 13.77μ1.7 24μ1.5 
F3 79.43μ2.78 13.11μ1.3 26μ2.0 
F4 77.1μ2.44 12.45μ1.6 27μ1.5 
F5 76.17μ2.86 12.45μ1.7 24μ1.9 
F6 77.85μ3.85 11.71μ1.4 27μ2.7 
F7 75.42μ3.01 12.77μ1.6 26μ1.9 
F8 73.16μ2.42 11.43μ1.8 29μ2.1 
F9 70.51μ2.10 12.54μ1.2 28μ2.5 
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Surface Morphology / (Scanning Electron Microscopy) All the formulations were found to be free flowing i.e. non sticky, 
spherical and white powdery in appearance as shown in Figure 3. 
 
 
Figure 2. Response surface plot showing effect of factorial variables (Drug : Polymer ratio and  concentration of stabilizer) on % drug entrapment 
(Y2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Figure 3. Scanning Electron Micrograph (SEM) of PLGA  NPs (F8). 
 
Thermal characterization of NPs  The DSC technique can provide qualitative and quantitative information about the physicochemical status of drug in NPs. The 
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related thermal transitions include melting, recrystallization, 
decomposition and out gassing or a change in heat capacity. DSC 
is useful to monitor different samples of same material to assess 
their similarities or differences or the effects of additives on the 
thermal properties of a material. Using the DSC analysis of drug, 
polymer materials and produced NPs, the nature of the drug inside 
the polymer matrix can be assessed, which may emerge as in solid 
solution, metastable molecular dispersion or crystallization. In order 
to identify the physical state of the drug within the selected 
nanoparticle formulations were subjected to DSC studies. A sharp 
and large onset/peak/endset peak of ACV at 
246.16/252.15/258.14oC as shown in Figure 4 was obtained which 
is corresponding to melting temperature of ACV (249ºC). However, 
the melting peak of the drug was absent in the DSC thermograms 
(Figure 4) of formulation F5, F8 and F9 indicating that the drug was 
dispersed in the NPs as an amorphous form. 
 
 
 
Figure 4. DSC thermograms of drug loaded PLGA NPs. 
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X-Ray Diffraction (XRD) studies 
The DSC studies revealed that the drug loaded in NPs was in an 
amorphous form. This phenomenon was further confirmed by X-ray 
diffraction patterns. The crystal peak (7.0À, 10.5À, 23.9À, 
26.2À,29.2À) of ACV was clearly observed in the X-ray data as 
shown in Figure 5 However, the diffraction patterns of ACV loaded 
PLGA NPs (Figure 5) did not contain any peaks associated with 
crystals of the drug, suggesting that the drug was amorphous in the 
polymer matrix. 
 
 
  Figure 5. X-ray diffraction of drug loaded PLGA NPs. 
In vitro drug release studies and release kinetics 
Drug release from NPs and subsequent biodegradation are 
important for developing the successful formulations. The release 
rate of NPs depends upon i) desorption of the surface-
bound/adsorbed drug; ii) diffusion through the nanopaticle matrix; 
iii)diffusion(in case of nanocapsules) through the polymer wall; 
iv)nanoparticle matrix erosion:and v) a combined erosion/diffusion 
process.[13] Thus, diffusion and biodegradation govern the 
process of drug release. 
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Table 4. Pharmacokinetic Parameters following oral administration of test formulations, conventional tablet and intravenous administration of 
pure drug. 
 
The AUC
 
values for oral administration of Commercial Tablet 
Zovirax®, Formulation F5, Formulation F8 and Formulation F9 
found to be 6.53, 15.22, 17.96 and 16.81 øg.hr/mL respectively. 
These values clearly indicated the improvement in bioavailability of 
ACV from prepared formulation when compared to conventional 
commercial tablet. 
The relative bioavailability (Fr) of ACV was found to be 201.44%, 
276.38% and 259.09% for Formulation F5, F8 and F9 respectively. 
It was observed that, % absolute bioavailability of test formulations 
was significantly higher than commercial tablet Zovirax® i.e 4.29%, 
4.92% and 4.61% respectively for formulation F5, F8 and F9, 
whereas Zovirax® has only 1.78% absolute bioavailability. These 
results indicate that the bioavailability of ACV was improved 
significantly when administered as a PLGA NPs. 
 Other pharmacokinetic parameters, like volume of distribution 
(Vd), total body clearance (Cl/F), has been calculated with the help 
of WinNonlin software (Standard version1.5), shows test 
formulations (F5, F8 and F9) have higher volume of distribution 
than conventional tablets. 
Conclusion 
ACV loaded NPs were prepared by the solvent deposition method. 
The application of factorial design gave a statistically systematic 
approach for the formulation of NPs with desired particle size and 
high entrapment efficiency. Drug: polymer ratio and concentration 
of stabilizer were found to influence the particle size and 
entrapment efficiency of ACV loaded PLGA NPs but the 
concentration of stabilizer had greater influence on both dependent 
variables (Particle size and Drug entrapment) as compared to 
Drug:Polymer rato. In vitro drug release study of selected factorial 
formulations (F5, F8, F9) showed 58.48 %, 66.54%, and 62.92% 
release respectively in 32 hrs. The release was found to follow first 
order release kinetics with fickian diffusion mechanism for all 
batches. The in vivo studies of selected formulations followed by 
comparison with pharmacokinetic parameters like AUC, % relative 
bioabaliability, % absolute bioavailability, t1/2, MRT of conventional 
tablet (Zovirax®), revealed that 2.6 folds improvement in 
bioavailability which results in probable decrease in dose and 
dosing frequency due to controlled particle size, entrapment 
efficiency and sustain drug release pattern. 
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Pharmacokinetic 
Parameters F5 F8 F9 Zovirax Pure Drug (I.V.) 
AUC
(0-24)
  
(øg.h/mL) 
15.22μ0.2160 17.96μ0.1760 16.81μ0.363 6.53μ0.515 42.72μ3.12 
AUC 
(0-¥) 
(øg.h/mL) 
45.55μ3.99 64.77μ2.68 51.54μ5.41 6.90μ0.681 47.16μ3.84 
AUMC(øg.h/mL) 152.65μ4.12 193.96μ2.57 178.65μ5.43 35.48μ5.46 62.71μ5.14
AUMC
(0-¥) 
(øg.h/mL) 
2145μ435.978 5002.94μ390.290 3317μ757.978 47.29μ11.21 80.31μ7.59 
C
max
(øg/mL) 1.01μ0.0082 1.22μ0.0082 1.06μ0.013 1.39μ0.025 26.37μ1.95 
T 
max
 (h) 3.00μ0.00 3.00μ0.00 3.00μ0.00 1.00μ0.00 0.0083μ0.00 
%  Relative bioavailability 201.44μ92 276.38μ22.89 259.09μ26.9 - - 
%  Absolute bioavailability 4.297μ0.457 4.92μ0.299 4.610μ0.278 1.78μ0.16 - 
Ka(h
-1
) 0.568μ0.043 1.666μ0.0438 0.732μ0.022 1.466μ0.0438 - 
t
1/2 
(h) 4.96μ1.43 6.1μ0.156 5.2μ0.230 3.12μ0.55 1.2μ0.9 
Kel(h
-1
) 0.018μ0.0011 0.012μ0.005 0.015μ0.001 0.140μ0.016 0.561μ0.00 
MRT (h) 10.48μ0.064 10.79μ0.040 10.61μ0.097 5.4μ0.43 1.49μ0.09
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